Articles

Potential Effient rival shows promise in study

A study showing Johnson & Johnson and Bayer AG’s blood-thinner Xarelto succeeded where rival drugs failed could give the companies entry to a $1 billion-plus market where Eli Lilly already competes.

Read More

Lilly hid Zyprexa’s diabetes risks, family’s lawyer argues

Eli Lilly and Co. hid the diabetes risks of Zyprexa to protect sales, a lawyer for the family of a 20-year-old patient who died while taking the medicine told a jury in the first case to go to trial over the drug. The attorney asked jurors to award the family $40 million in compensatory damages.

Read More

Ortho firms pull back on doc payments

The number of payments in excess of $1 million didn’t change substantially from year to year, but orthopedic companies sharply cut their fees to surgeons who received the smallest amounts.

Read More

Q&A

Dr. Ed Kowlowitz, owner and medical director of the Center for Pain Management in Indianapolis, recently challenged a regional Medicare reimbursement policy and, surprisingly, won. He spoke with IBJ about the experience, as well how his three-physician practice is growing even while many physician practices are selling to hospitals.

Read More

FDA gets new report on Lilly diabetes drug

Drugmakers Eli Lilly and Co. and Amylin Pharmaceuticals Inc. said Monday that patients taking their potential once-weekly diabetes treatment, Bydureon, saw a significant improvement in cardiovascular risk factors.

Read More

Private firm with Medicaid deal gets state help

Officials with the Missouri Department of Health and Senior Services say they had to hire 13 temporary workers and shift as many as 20 state workers from their regular jobs after withering consumer complaints against SynCare LLC of Indiana.

Read More